Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Eloxx Pharmaceuticals, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −3 vs. Q1 2023
- Shares held
- 237.5K
- −29.4K (−11.0%) vs. Q1 2023
- Total value
- $924.2K
- +$252.7K (+37.6%) vs. Q1 2023
- New holders
- 0
- 4 more added
- Sold out
- 3
- 0 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELOX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $34.7M |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $0 |
| Q2 2024 | 1 | $43 |
| Q1 2024 | 1 | $62 |
| Q4 2023 | 4 | $109.0K |
| Q3 2023 | 18 | $2.50M |
| Q2 2023 | 16 | $924.2K |
| Q1 2023 | 19 | $671.5K |
| Q4 2022 | 19 | $476.7K |
| Q3 2022 | 32 | $2.14M |
| Q2 2022 | 32 | $3.51M |
| Q1 2022 | 36 | $8.42M |
| Q4 2021 | 39 | $11.7M |
| Q3 2021 | 41 | $26.0M |
| Q2 2021 | 47 | $33.2M |
| Q1 2021 | 38 | $28.7M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Eloxx Pharmaceuticals, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Silverarc Capital Management, LLC | 54,075 | $210.4K | 0.07% | 00.0% | Unchanged |
| Menora Mivtachim Holdings Ltd. | 52,355 | $203.7K | 0.00% | 00.0% | Unchanged |
| American Financial Group Inc | 37,000 | $144.0K | 0.04% | 00.0% | Unchanged |
| Altshuler Shaham Ltd | 25,123 | $97.7K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 20,686 | $80.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 20,259 | $78.8K | 0.00% | +19+0.1% | Added |
| Clal Insurance Enterprises Holdings Ltd | 14,626 | $57.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 8,890 | $34.6K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,479 | $9.64K | 0.00% | +62+2.6% | Added |
| Wells Fargo & Company | 1,168 | $4.54K | 0.00% | +1+0.1% | Added |
| Royal Bank of Canada | 786 | $3.00K | 0.00% | +743+1,727.9% | Added |
| Morgan Stanley | 79 | $307 | 0.00% | 00.0% | Unchanged |
| Meeder Asset Management Inc | 15 | $58 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 4 | $16 | 0.00% | 00.0% | Unchanged |
| NewSquare Capital LLC | 1 | $4 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 1 | $4 | 0.00% | 00.0% | Unchanged |
| Harel Insurance Investments & Financial Services Ltd. | 0 | $0 | 0.00% | −29,410−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −469−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −371−100.0% | Sold out |